Tacrolimus recalls

Tacrolimus products have been recalled 6 times, most recently on 17 Jan 2024. The recalling company is usually Dr. Reddy's Laboratories.

Total recalls6since 2012

Last 12 months0reported

Class I00% of total

Ongoing2latest 17 Jan 2024

Recalls per month, last 24 months

click a bar for that month

0Nov '24 0 0 0Feb 0 0 0May 0 0 0Aug 0 0 0Nov 0 0 0Feb 0 0 0May 0 0 0Aug 0 0

Severity split

Class I 0 0%Class II 3 50%Class III 3 50%

Why tacrolimus is recalled

Other Reasons583%
Potency & Assay117%

Companies

Product types

Eye Drops117%

By year

2024117%
2023117%
2022117%
2021117%
2020117%
2012117%

Ongoing tacrolimus recalls

2 active

Reported	Class	Recall	Company	Reason	Where
1 Mar 2023Drug	CLASS II	Tacrolimus Capsules, USP, 0.5 mg recalled by Dr. Reddy's LaboratoriesTacrolimus	Dr. Reddy's Laboratories	Other	Nationwide
10 Aug 2022Drug	CLASS III	Tacrolimus Ointment, 0.1%, For Dermatological Use Only recalledTacrolimus	Glenmark Pharmaceuticals Inc., USA	Other	Nationwide

All tacrolimus recalls, newest first

6 total

Reported	Class	Recall	Company	Reason	Where
17 Jan 2024Drug	CLASS II	Tacrolimus Capsules, USP 1mg recalled by Dr. Reddy's LaboratoriesTacrolimus	Dr. Reddy's Laboratories	Other	Nationwide
1 Mar 2023Drug	CLASS II	Tacrolimus Capsules, USP, 0.5 mg recalled by Dr. Reddy's LaboratoriesTacrolimus	Dr. Reddy's Laboratories	Other	Nationwide
10 Aug 2022Drug	CLASS III	Tacrolimus Ointment, 0.1%, For Dermatological Use Only recalledTacrolimus	Glenmark Pharmaceuticals Inc., USA	Other	Nationwide
6 Jan 2021Drug	CLASS III	Strides Pharma products recalledTacrolimus	Strides Pharma	Other	PA
1 Apr 2020Drug	CLASS III	Tacrolimus Capsules, USP 5mg recalled by Mylan PharmaceuticalsTacrolimus	Mylan Pharmaceuticals	Other	Nationwide
5 Dec 2012Drug	CLASS II	Tacrolimus Capsules 0.5 mg recalled by MylanTacrolimus	Mylan	Potency & Assay	PR

About this list

Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.